RSV sends millions of children under 5 to the hospital worldwide each year, and in the US the infant hospitalization rate is as high as 1 in 38 during the first season. Even when infants look like they are “just” getting over a cold, RSV can lead to wheezing in 20 to 30 percent and trigger apnea in 10 percent of hospitalized preterm babies. Let’s break down what the latest RSV statistics reveal across ages, severity, outcomes, and costs.
Key Takeaways
- RSV leads to 2-3 million hospitalizations worldwide in children under 5 yearly
- In US infants under 1 year, RSV hospitalization rate is 1 in 38 during first season
- RSV bronchiolitis requires mechanical ventilation in 2-5% of hospitalized infants
- RSV diagnosis sensitivity of rapid antigen test is 80-90% in children
- PCR testing detects RSV with 95-100% sensitivity in nasopharyngeal swabs
- RSV IgM serology has low specificity (50-70%) for acute infection
- In the United States, RSV accounts for an estimated 58,000-80,000 hospitalizations among children younger than 5 years each year
- Globally, RSV is responsible for approximately 33 million lower respiratory tract infections in children under 5 years annually
- In the US, nearly all children are infected with RSV by their second birthday
- Palivizumab prophylaxis efficacy 39-82% against RSV hospitalization
- Nirsevimab single-dose prevents 75-80% RSV hospitalizations in infants
- RSVpreF vaccine (Abrysvo) 81.8% efficacy in maternal immunization
- Preterm infants have 10-fold higher RSV hospitalization risk
- Children with chronic lung disease face 5-10 times higher RSV hospitalization rates
- Immunocompromised children have 2-4 fold increased RSV severity
RSV fuels massive pediatric hospitalizations, and prevention through vaccines and antibodies can sharply reduce severe disease.
Related reading
01 · Category
Clinical Impact27 stats
01
RSV leads to 2-3 million hospitalizations worldwide in children under 5 yearly
02
In US infants under 1 year, RSV hospitalization rate is 1 in 38 during first season
03
RSV bronchiolitis requires mechanical ventilation in 2-5% of hospitalized infants
04
20-30% of RSV-infected children under 2 develop wheezing episodes post-infection
05
RSV pneumonia mortality in preterm infants is up to 1-2%
06
Hospital length of stay for RSV in infants averages 3-5 days
07
RSV causes apnea in 10% of hospitalized preterm infants under 35 weeks GA
08
In adults over 65, RSV leads to 6.5% ICU admission rate among hospitalized cases
09
RSV infection results in 40% readmission rate within 30 days for infants
10
Bronchiolitis from RSV accounts for 48% of infant hospitalizations under 12 months
11
RSV lower respiratory tract disease severity score averages 6.5 in hospitalized children
12
75% of RSV hospitalizations in children occur in those under 5 months old
13
RSV causes acute respiratory failure in 15% of elderly hospitalized patients
14
Infant RSV infection doubles risk of asthma development by age 6
15
RSV otitis media complication occurs in 30-50% of cases in young children
16
Hospital costs for RSV in US infants average $11,000per admission
17
RSV leads to 10-20% incidence of secondary bacterial infections in hospitalized kids
18
In congenital heart disease infants, RSV mortality is 5-10%
19
RSV causes 25% of COPD exacerbations in adults
20
Pediatric RSV ICU stay averages 7-10 days
21
RSV myocarditis reported in 1-2% of severe pediatric cases
22
50% of RSV-positive wheezing infants require supplemental oxygen
23
RSV encephalopathy occurs in 0.6-2% of hospitalized children
24
Annual US RSV healthcare costs exceed $1 billion for children under 5
25
RSV seizure incidence in infants is 2-3%
26
In elderly, RSV pneumonia has 30-day mortality of 8-10%
27
RSV hospitalization oxygen requirement in 70% of infants under 3 months
Interpretation
Clinical Impact Interpretation
In summary, RSV is not merely a common cold but a stealthy respiratory heavyweight that lands one in thirty-eight American babies in the hospital, racks up billion-dollar bills, and can cast a long shadow of wheeze and worry far beyond the initial infection.
02 · Category
Diagnostics26 stats
01
RSV diagnosis sensitivity of rapid antigen test is 80-90% in children
02
PCR testing detects RSV with 95-100% sensitivity in nasopharyngeal swabs
03
RSV IgM serology has low specificity (50-70%) for acute infection
04
Multiplex PCR panels identify RSV in 25-40% of pediatric respiratory samples
05
Chest X-ray shows hyperinflation in 70% of RSV bronchiolitis cases
06
RSV viral load peaks at day 2 post-symptom onset, quantifiable by qPCR
07
BinaxNOW RSV rapid test specificity is 94% but sensitivity 66% in infants
08
Direct fluorescent antibody (DFA) test for RSV has 90% sensitivity in children
09
RSV A subtype detected in 60% of cases, B in 40% via genotyping PCR
10
Blood gas analysis shows hypoxemia (PaO2 <60 mmHg) in 40% severe RSV
11
Nasal wash vs swab: washes have 20% higher RSV detection yield
12
RSV fusion protein sequencing differentiates clades ON1 and BA
13
Loop-mediated isothermal amplification (LAMP) for RSV has 98% specificity
14
Elevated CRP (>40 mg/L) in only 20% RSV vs 60% bacterial pneumonia
15
RSV genome sequencing turnaround time averages 48 hours in labs
16
Procalcitonin <0.25 ng/mL supports viral RSV diagnosis (90% NPV)
17
FilmArray RP panel detects RSV in 2 hours with 97% accuracy
18
RSV seroprevalence by ELISA: 100% by age 2 in developed countries
19
Lung ultrasound shows B-lines in 85% RSV bronchiolitis cases
20
Point-of-care PCR (e.g., ID NOW) RSV sensitivity 92%, specificity 98%
21
RSV culture from nasopharyngeal specimen takes 3-10 days, low sensitivity 50%
22
Hyperoxia test (FiO2 100%) distinguishes cardiac vs pulmonary RSV causes
23
Next-gen sequencing identifies RSV co-infections in 30% samples
24
RSV antibody avidity testing confirms primary infection (>50% avidity)
25
Bronchoalveolar lavage RSV PCR positive in 70% ventilated infants
26
Digital droplet PCR quantifies RSV load >10^6 copies/mL in severe disease
Interpretation
Diagnostics Interpretation
The sobering reality of RSV diagnostics is that while PCR tests remain our reliable sentinel, our quest for the perfect rapid, point-of-care test is a bit like trying to catch a mischievous toddler with a butterfly net—often you'll get them, but they're usually three steps ahead and you're left with a lot of false reassurance and one very clear chest X-ray.
03 · Category
Epidemiology30 stats
01
In the United States, RSV accounts for an estimated 58,000-80,000 hospitalizations among children younger than 5 years each year
02
Globally, RSV is responsible for approximately 33 million lower respiratory tract infections in children under 5 years annually
03
In the US, nearly all children are infected with RSV by their second birthday
04
RSV causes about 3,000-7,000 deaths in children under 5 years worldwide each year
05
During the 2021-2022 RSV season, hospitalizations in US infants under 6 months increased by 1.8 times compared to pre-pandemic levels
06
In Europe, RSV incidence peaks in winter, with 1-2% of infants hospitalized annually
07
RSV detection rates in US outpatient settings for children under 2 years reached 2.9% during peak seasons
08
In low-income countries, RSV-associated hospitalization rates for infants are 10-20 times higher than in high-income countries
09
Australia reports over 10,000 RSV hospitalizations in children under 5 annually
10
In the UK, RSV causes around 18,000 hospital admissions in infants under 1 year per season
11
RSV positivity in global sentinel surveillance was 3.2% among children under 5 with acute respiratory illness
12
In Brazil, RSV accounts for 20-30% of pneumonia hospitalizations in children under 2
13
Canada sees 2,500-3,500 RSV-related pediatric ICU admissions yearly
14
In South Africa, RSV hospitalization rate for infants is 22.8 per 1,000
15
Japan reports RSV as cause of 77% of bronchiolitis cases in infants
16
In the US, RSV-related ED visits for adults over 65 tripled during 2022-2023 season
17
Global RSV burden estimated at 118,000 deaths in children under 5 in 2019
18
In India, RSV positivity in hospitalized pneumonia cases is 15-25%
19
New Zealand has RSV hospitalization rates of 25 per 1,000 infants under 12 months
20
In France, RSV causes 29,000 hospitalizations annually in children under 15
21
RSV infects 64 million people globally each year across all ages
22
In the Netherlands, 1 in 300 infants under 6 months is hospitalized for RSV
23
China reports RSV as 28% of viral respiratory infections in children
24
In Kenya, RSV hospitalization incidence is 7.2% in children under 5
25
US adults over 75 have RSV hospitalization rate of 116 per 100,000
26
RSV season in Southern Hemisphere starts December-February
27
In Germany, RSV accounts for 40% of acute bronchitis hospitalizations in infants
28
Global pediatric RSV outpatient visits exceed 20 million annually
29
In the Philippines, RSV is detected in 12% of severe pneumonia cases
30
RSV causes 14,000 deaths in US adults over 65 annually
Interpretation
Epidemiology Interpretation
While RSV seems determined to meet every child on Earth by their second birthday, its global hospitality tour leaves behind a staggering trail of hospitalizations and heartbreaking losses that demand a serious response despite the virus’s universal familiarity.
More related reading
04 · Category
Prevention/Treatment28 stats
01
Palivizumab prophylaxis efficacy 39-82% against RSV hospitalization
02
Nirsevimab single-dose prevents 75-80% RSV hospitalizations in infants
03
RSVpreF vaccine (Abrysvo) 81.8% efficacy in maternal immunization
04
Hand hygiene reduces RSV transmission by 16-20% in households
05
Exclusive breastfeeding for 6 months lowers RSV hospitalization by 40%
06
Arexvy RSV vaccine 82.6% efficacy against LRTI in adults 60+
07
High-flow nasal cannula reduces intubation by 50% in RSV bronchiolitis
08
Ribavirin aerosol reduces RSV severity by 30% in high-risk infants (controversial)
09
Avoiding daycare first 6 months reduces RSV infection by 37%
10
Vitamin D supplementation (400 IU/day) cuts RSV risk by 56% in deficient infants
11
Heliox therapy improves RSV bronchiolitis scores by 25%
12
RSV immunoglobulin IV (Respigam) 63% reduction in CHD infants
13
Nebulized hypertonic saline 3% reduces hospital stay by 0.4 days in RSV
14
Maternal RSV vaccination at 32-36 weeks gestation 69% effective
15
Face masks in households lower RSV spread by 10-15%
16
Epinephrine nebulization no benefit over saline in RSV (RR 0.79, NS)
17
Palivizumab 5 monthly doses cover 85-90% RSV season protection
18
Remdesivir IV shortens RSV viral shedding by 1.3 days in immunocompromised
19
Cohorting RSV-positive infants reduces nosocomial transmission by 65%
20
RSVpreF booster sustains 50% efficacy year 2 in adults
21
Probiotics (Lactobacillus) reduce RSV incidence by 30% in trials
22
Bronchodilators ineffective in RSV bronchiolitis (no symptom relief)
23
Steroids (corticosteroids) do not reduce RSV hospital stay (RR 0.92)
24
Contact precautions lower hospital RSV transmission by 50%
25
Molnupiravir phase 2 reduces RSV load but not symptoms significantly
26
Nirsevimab 200mg dose protects 79% against medical encounters
27
RSV oral vaccine candidate (DS-7) 67% efficacy in cotton rats
28
CPAP non-invasive ventilation cuts escalation to intubation by 40%
Interpretation
Prevention/Treatment Interpretation
While a kaleidoscope of modern interventions like nirsevimab shots, maternal vaccines, and good old handwashing offer layered and often substantial defenses against RSV, the humble, powerful act of breastfeeding for six months proves surprisingly competitive in the prevention arms race.
05 · Category
Risk Groups24 stats
01
Preterm infants have 10-fold higher RSV hospitalization risk
02
Children with chronic lung disease face 5-10 times higher RSV hospitalization rates
03
Immunocompromised children have 2-4 fold increased RSV severity
04
Infants with hemodynamically significant congenital heart disease have 4-fold RSV hospitalization risk
05
Adults over 65 years have 4-8 times higher RSV hospitalization risk than younger adults
06
Adults with chronic heart failure have 13 times increased RSV mortality risk
07
Neuromuscular disorder patients have 6-fold higher RSV ICU admission rates
08
HIV-infected children under 2 have 2.5 times RSV hospitalization risk
09
Obese adults (BMI>30) have 1.7 times higher RSV hospitalization odds
10
Infants under 3 months have 10-20 times higher hospitalization risk per infection
11
Down syndrome children have 3-5 fold elevated RSV severity
12
COPD patients have 8.9 times increased RSV-associated mortality
13
Cancer patients over 65 have 2.5 times RSV hospitalization risk
14
American Indian/Alaska Native infants have 1.5-2 times higher RSV hospitalization rates
15
Sickle cell disease children have 4-fold RSV risk
16
Pregnant women with obesity have infants with higher RSV risk
17
Adults in long-term care facilities have 9-fold RSV attack rate
18
Cystic fibrosis infants under 2 have 5-10 fold RSV hospitalization risk
19
Diabetic adults have 5.2 times higher RSV mortality
20
Infants of smoking mothers have 2-fold increased RSV hospitalization
21
Renal failure patients have 3-fold RSV severity increase
22
Male infants have 1.3 times higher RSV hospitalization risk than females
23
Indigenous Australian children have 2-3 times higher RSV rates
24
Liver transplant recipients have 20% RSV complication rate
Interpretation
Risk Groups Interpretation
These statistics paint a grim and universal portrait of RSV as a ruthless opportunist, preying with mathematical precision on the very young, the old, and anyone whose body is already engaged in a different battle.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Felix Zimmermann. (2026, February 13). Rsv Statistics. Gitnux. https://gitnux.org/rsv-statistics
MLA
Felix Zimmermann. "Rsv Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/rsv-statistics.
Chicago
Felix Zimmermann. 2026. "Rsv Statistics." Gitnux. https://gitnux.org/rsv-statistics.
Sources & references
42 datasets cited across this report · attribution is report-level